In-vitro efficacy of cefotiam in combination with four aminoglycosides on staphylococci and Gram-negative bacteria.
D000583:Amikacin / Q000494:pharmacology; D000617:Aminoglycosides / Q000494:pharmacology*; D002439:Cefotaxime / Q000031:analogs & derivatives* / Q000494:pharmacology; D015310:Cefotiam; D004347:Drug Interactions; D004755:Enterobacteriaceae / Q000187:drug effects*; D004926:Escherichia coli / Q000187:drug effects; D005839:Gentamicins / Q000494:pharmacology; D007711:Klebsiella pneumoniae / Q000187:drug effects; D009428:Netilmicin / Q000494:pharmacology; D011511:Proteus / Q000187:drug effects; D013210:Staphylococcus / Q000187:drug effects*; D014031:Tobramycin / Q000494:pharmacology
D000617:Aminoglycosides; D005839:Gentamicins; D009428:Netilmicin; D000583:Amikacin; D015310:Cefotiam; D002439:Cefotaxime; D014031:Tobramycin